All In Biotech

Drug Trial Radar · NCT00669643

Uniform Multidrug Therapy Regimen for Leprosy Patients

Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients

Last checked: Nov 19, 2026Latest source record: Jun 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 859 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

859

Actual

Start

Feb 2007

Primary completion

Sep 2012

Study completion Dec 31, 2016

Sponsor

Lead sponsor
University of BrasiliaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico; Ministry of Science and Technology, Brazil; Ministry of Health, Brazil; Fundação Alfredo da Matta, Manaus, Brazil; Instituto de Dermatologia Dona Libania, Fortaleza, Brazil
First posted
Apr 30, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized trial is to verify if leprosy patients, despite of their classification, can be treated with the same regimen without compromising patient cure and acceptability of the treatment. At present, patients classified as multibacillary leprosy are treated for 12 months with three drugs, and patients classified as paucibacillary leprosy are treated for 6 months with two drugs. The study is going to test a unified regimen for paucibacillary and multibacillary patients by treating leprosy patients with three drugs for 6 doses.

Conditions

  • Leprosy

Interventions

  • PB 6 doses - Rifampicin and DapsoneDrug

    Adult: 6 doses; 1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone; Children: 6 doses; 1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone

  • PB 6 doses - Rifampicin, Clofazimine and DapsoneDrug

    Adult: 6 doses; 1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine; Children: 6 doses; 1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine

  • MB 12 doses - Rifampicin, Clofazimine and DapsoneDrug

    Adult: 12 doses; 1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine; Children: 12 doses; 1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine

  • MB 6 doses - Rifampicin, Clofazimine and DapsoneDrug

    Adult: 6 doses 1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine Children: 6 doses 1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. RelapseTime frame: 5 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Centro de Referência Nacional Alfredo da Matta - FUAM

    Manaus, Amazonas, Brazil

  • Centro de Referência Nacional Dona Libânia - CDERM

    Fortaleza, Ceará, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.